WebApr 12, 2024 · BETHESDA, Md., April 12, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial … WebApr 6, 2024 · A high-level overview of Gain Therapeutics, Inc. (GANX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Akero Therapeutics (NASDAQ:AKRO) Receives Outperform Rating …
WebMar 23, 2024 · Gain Therapeutics, Inc. Reports Full Year 2024Financial Results and Business Update. $36.88 Million in Cash as of December 31, 2024, provides runway into second half of 2024 and a strong cash position to transition the Company’s lead program into clinical trials. Compelling preclinical data presented on lead program GBA1 … WebMar 21, 2024 · Gain Therapeutics, Inc. is transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating … db2 timestamp where句
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue …
WebOn April 20th, 2024, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology targets. Gain will be using its proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to ... WebGain Therapeutics will be providing an update on our lead compound in development for GBA-associated Parkinson’s disease, GT-02287 at the Jefferies Global Healthcare … WebOn April 20th, 2024, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology … gears of war 4 player count